07:00 , Jul 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Toll-interleukin 1 receptor (TIR) domain containing adaptor protein (TIRAP); toll-like receptor 2 (TLR2)

Infectious disease INDICATION: Influenza virus In vitro and mouse studies suggest a peptide derived from the TIR domain of TLR2 could help treat influenza infection. In human cell-based assays, screening of a peptide library derived...
07:00 , May 16, 2013 |  BC Innovations  |  Cover Story

Eritoran insight for influenza treatment

A University of Maryland School of Medicine team has used a toll-like receptor 4 antagonist to treat influenza in mice. 1 The results provide a repurposing opportunity for Eisai Co. Ltd. 's toll-like receptor 4...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Toll-interleukin 1 receptor domain containing adaptor protein (TIRAP); toll-like receptor 4 (TLR4); TLR2; tumor necrosis factor-a (TNF-a); IL-6 In vitro and mouse studies suggest...